Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
2024年3月18日 - 7:30PM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced the appointment of Dr. Huma Qamar as Chief Medical
Officer (CMO).
“I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said
Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and
Co-Founder of Ocugen. “This appointment recognizes her
invaluable contributions to building a strong clinical team,
overseeing a well-conducted Phase 1/2 gene therapy trial, and
establishing relationships with leading medical and academic
institutions and key opinion leaders.”
Dr. Qamar is a distinguished healthcare professional with a rich
background in clinical research, having contributed her expertise
to esteemed Ivy League institutions including Yale University,
Harvard University, and University of Pennsylvania. Her expertise
encompasses the development of Phase I-IV clinical protocols and
execution of clinical studies, FDA inspections, and effective
leadership of medical affairs teams.
“Having been a part of Ocugen’s mission and vision for more than
three years now, it’s a pleasure to lead Ocugen’s clinical
development at this pivotal time,” said Dr. Qamar. “I am committed
to addressing patients’ unmet medical needs and bringing novel
modifier gene therapy products to the market globally.”
Dr. Qamar has expertise in multiple therapeutic areas, including
gene and cell therapy, vaccines, oncology (Heme-Onc, CAR-T, rare
tumors, sarcoma, melanoma, women's health, GU & GI, fetal
oncology), rheumatology, dermatology, neurology, cardiology,
hepatology, and infectious diseases.
“Dr. Qamar has a deep understanding of Ocugen’s ongoing clinical
trials and a close working relationship with the clinical and
regulatory teams, both of which are fundamentally important to the
success of Ocugen’s programs,” said Dr. Prabhavathi Fernandes,
Independent Lead Director, Ocugen board. “I’m confident that her
determination and dedication will bring the Company’s
first-in-class candidates through the upcoming clinical milestones
to deliver on Ocugen’s long-term strategy.”
Prior to joining Ocugen, Dr. Qamar was Senior Vice President,
Head of R&D at FSD Pharma—demonstrating her commitment to
advancing scientific innovation and pharmaceutical development.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies,
biologics, and vaccines that improve health and offer hope for
patients across the globe. We are making an impact on patients’
lives through courageous innovation—forging new scientific paths
that harness our unique intellectual and human capital. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with a single product, and we are
advancing research in infectious diseases to support public health
and orthopedic diseases to address unmet medical needs. Discover
more at www.ocugen.com and follow us
on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, which are subject to risks and uncertainties. We may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
過去 株価チャート
から 8 2024 まで 9 2024
Ocugen (NASDAQ:OCGN)
過去 株価チャート
から 9 2023 まで 9 2024